Amarastesia – cerAMvix: an atraumatic cervical dilator and uterine access device
The Problem
Cervical dilation during uterine access is the most critical step in many gynaecological procedures. Each year, 100 million women undergo cervical dilation, an essential step in many diagnostic and surgical gynaecological procedures. However, dilation remains the most critical step: 50% of complications occur during this phase, including uterine perforation, hemorrhage, and cervical laceration.
In addition, women associate cervical dilation with extreme discomfort, with pain being the cause for up to 84% of unsuccessful procedures. Amarastesia’s CEO and Founder, Dr. Roxana Belciu-Kerns directly witnessed these dramatic complications during gynecological interventions, challenged to find a solution to provide safer cervical dilation, protect anatomical tissues and improve access and visibility for the instruments used during subsequent procedures.
The Project
Amarastesia has developed CerAMvix, a disposable, atraumatic and minimally invasive cervical dilator and uterine access device. It creates a protected passageway through the cervix for surgical and diagnostic instruments, minimizing tissue trauma.
The device also integrates direct visualisation, giving clinicians greater control when accessing the uterine cavity. Building on a preclinical proof of concept, the project will refine CerAMvix and validate its performance in conditions that reflect clinical use.
The Impact
CerAMvix could make gynaecological procedures safer, less painful and more predictable, reducing complications for patients and healthcare costs associated with general anaesthesia, main operating room and hospital nursing care.
For clinicians, it could improve workflows and save operating-room time, while modernizing women’s health, a field where many instruments have changed very little over two centuries.
The Result
Thanks to a highly competitive application supported by Evolution Europe’s experts, the project submitted a highly competitive application and secured CHF 876,000 in funding—equivalent to over €900,000, through the Innosuisse Start-up Innovation Projects programme in March 2026. This funding will support the technical and clinical development of CerAMvix, generate further evidence of its safety and performance, and prepare the device for regulatory approval and commercialisation.